• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Chimerix, Inc.

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
March 21, 2025
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2025
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
February 18, 2025
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
January 29, 2025
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2025
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Speak Today at The White House Cancer Moonshot Forum
January 13, 2025
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
December 30, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
December 09, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
November 11, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 07, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
November 01, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 13, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
August 06, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 30, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
May 01, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
April 24, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Appoints Marc D. Kozin to Board of Directors
March 21, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX UFPT
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
February 29, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
February 27, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
February 22, 2024
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Appoints Lisa Decker to Board of Directors
December 29, 2023
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
December 04, 2023
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 24, 2023
From Chimerix, Inc.
Via GlobeNewswire
Tickers CMRX
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap